Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Daptomycin

FDA-approved product (powder, intravenous), marketed as Cubicin, Cubicin Rf, Daptomycin and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Daptomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial endocarditis
  • Bacteriemia
  • Endocarditis
  • Gram-positive bacterial infections
  • Infection
  • Infective endocarditis
  • Skin disease caused by bacterial infection
  • Soft Tissue Infections

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibacterials
FDA pharmacologic class
Lipopeptide Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XX09; FDA class Lipopeptide Antibacterial

Repurposing investigation

Daptomycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • E. coli48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Daptomycin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Daptomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy

    NCT00296049 · start 2005-07

    Registered record
    Registry ID
    NCT00296049
    Conditions
    Infection; Neutropenia; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions
    daptomycin; vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2005-07
    Completion
    2006-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Neutropenia; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventiondaptomycin; vancomycin
    PhaseNot applicable
    Registry statusWithdrawn

  • Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

    NCT00261807 · start 2005-06

    Registered record
    Registry ID
    NCT00261807
    Conditions
    Fasciitis, Necrotizing; Severe Necrotizing Skin and Soft Tissue Infections; Fournier's Gangrene
    Interventions
    Daptomycin 6mg/kg/day
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-06
    Completion
    2008-05
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFasciitis, Necrotizing; Severe Necrotizing Skin and Soft Tissue Infections; Fournier's Gangrene
    InterventionDaptomycin 6mg/kg/day
    PhaseNot applicable
    Registry statusCompleted

  • Cubicin(R) for Complicated Post-surgical Wound Infections

    NCT00651131 · start 2004-06-01

    Registered record
    Registry ID
    NCT00651131
    Conditions
    Wound Infections
    Interventions
    daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-06-01
    Completion
    2005-03-01
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWound Infections
    Interventiondaptomycin
    PhasePhase 4
    Registry statusTerminated

  • Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria

    NCT00055198 · start 2002-12-19

    Registered record
    Registry ID
    NCT00055198
    Conditions
    Gram-Positive Bacterial Infections
    Interventions
    daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2002-12-19
    Completion
    2004-01-26
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections
    Interventiondaptomycin
    PhasePhase 3
    Registry statusTerminated

  • Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus

    NCT00093067 · start 2002-03

    Registered record
    Registry ID
    NCT00093067
    Conditions
    Bacterial Endocarditis; Bacteremia
    Interventions
    daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-03
    Completion
    2005-02
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Endocarditis; Bacteremia
    Interventiondaptomycin
    PhasePhase 3
    Registry statusCompleted